Newsletter | October 22, 2024

10.22.24 -- A Look Into 'Mirror Molecules' May Lead To New Medicines

FEATURED EDITORIAL

Tracking The Latest Developments In CAR T Safety And Efficacy

Here are some updates on the industry's quest to enhance CAR T cells' ability to target and destroy cancer while reducing adverse effects.

INDUSTRY INSIGHTS

Simultaneous Spray Drying: Dry Powder Inhaler Combination Formulations

The simultaneous spray drying of multiple ingredients is a powerful technique for making inhaled products with multiple actives. Examine how novel techniques can make these products a reality.

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Discover how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.

Effects Of The Ongoing Pandemic On Bupivacaine HCI Supply

Throughout the pandemic, painkiller and sedative demands spiked. Drug manufacturers and CDMOs have become critical in efforts to stabilize the supply of Bupivacaine HCl and other essential drugs.

Efficient Viral Vector Production: A Rentschler Collaboration Story

Learn how a collaboration between Cytiva and Rentschler Biopharma facilitates the efficient and flexible production of viral vectors.

Harmonizing Regulatory Guidelines For Assay Validation

Explore a detailed process for validating ligand-binding assays, particularly for Fcγ receptor binding analytes or other structural isoforms.

FDA's Quality Management Maturity Program

Delve into the FDA's Quality Management Maturity (QMM) program’s benefits, the rating system’s evaluation criteria, advantages and challenges.

MOST POPULAR NEWS

A Look Into 'Mirror Molecules' May Lead To New Medicines

Alleo & Ubiquigent Enter AI-Driven Strategic Partnership

Eurofins Discovery Extends AI-Powered Integrated Drug Discovery Collaboration

For The First Time, A Drug Developed At UWM Enters FDA Clinical Trials

UroGen Announces FDA Acceptance Of Its New Drug Application For UGN-102

Innovation At A Price: The Hidden Costs Of Antibiotic Development

SystImmune, Inc. Announces FDA Clearance Of IND Application For BL-M11D1

Alnylam Submits sNDA To The U.S. FDA For Vutrisiran

A New Framework To Efficiently Screen Drugs

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives FDA Fast-Track Designation

Scripps Research Scientists Discover Chemical Probes For Previously 'Undruggable' Cancer Target

SOLUTIONS

Leading The Genomic Medicine Revolution

Cleanroom Capabilities And Expertise